Clinical significance of M2BPGi measurement in HCV treatment

Abstract

M2BPGi level decreased before and after DAA administration for hepatitis C, and such a decrease was similar in cases of liver cirrhosis and liver transplantation. The reduction rate of M2BPGi level was 45.6% at SVR 12, equivalent to those of ALT, AST and AFP levels. Although a M2BPGi ratio of 2 or more for before and after treatment decreased from 50.1% to 26.2%, the factors related to a M2BPGi ratio of 2 or more were in the order of AST, FIB-4, ALT, and AFP levels before treatment, which changed to FIB 4, ALB, and PLT levels after treatment. These results indicate that M2BPGi is affected by inflammation before treatment; however the effect of fibrosis is reflected rather than affected by inflammation after treatment.